Inhibition and degradation of NRAS with a pan-NRAS monobody. Read more about Inhibition and degradation of NRAS with a pan-NRAS monobody.
Editorial Expression of Concern: RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Read more about Editorial Expression of Concern: RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Read more about Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.
Retraction Note: Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin. Read more about Retraction Note: Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin.
AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis. Read more about AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis.
DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression. Read more about DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression.
A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer. Read more about A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer.
Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer. Read more about Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer.
Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer. Read more about Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer. Read more about LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.
